International Biotechnology Trust’s Denali Therapeutics DNLI Stock Holding History

International Biotechnology Trust’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$3.17M	Sell	154,000 -34,000	-18%	-$862K	1.07%	29
2023 Q2	$5.54M	Buy	188,000 +101,425	+117%	+$2.85M	1.69%	21
2023 Q1	$1.99M	Buy	86,575 +48,575	+128%	+$1.34M	0.56%	40
2022 Q4	$1.06M	Hold	38,000	–	–	0.33%	49
2022 Q3	$1.17M	Buy	38,000 +36,882	+3,299%	+$1.2M	0.37%	49
2022 Q2	$38K	Sell	1,118 -36,882	-97%	-$966K	0.4%	51
2022 Q1	$8.19M	Buy	38,000 +12,000	+46%	+$413K	1.85%	21
2021 Q4	$1.16M	Buy	+26,000	New	+$1.23M	0.26%	54

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

International Biotechnology Trust's DNLI Position: Q3 2023 in Review

International Biotechnology Trust reduced its Denali Therapeutics (DNLI) stake by 18% in Q3 2023, selling an estimated $862K and leaving 154,000 shares worth $3.17M. The position accounts for 1.07% of the portfolio, ranked #29.

International Biotechnology Trust first reported a position in DNLI in Q4 2021 and has held it in 8 quarters since. The position peaked at $8.19M in Q1 2022. 194 funds tracked by Wall St. Rank hold DNLI as of Q3 2023.

International Biotechnology Trust held 154,000 shares of Denali Therapeutics worth $3.17M as of Q3 2023.
International Biotechnology Trust sold 34,000 Denali Therapeutics shares in Q3 2023, an estimated $862K.
Denali Therapeutics made up 1.07% of International Biotechnology Trust's portfolio in Q3 2023, its #29 holding.
International Biotechnology Trust first reported a position in Denali Therapeutics in Q4 2021 and has held it in 8 quarters since.
International Biotechnology Trust's Denali Therapeutics position peaked at $8.19M in Q1 2022.
194 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.